Holm-Jorgensen Rasmus 4
4 · Acrivon Therapeutics, Inc. · Filed Jun 20, 2023
Insider Transaction Report
Form 4
Holm-Jorgensen Rasmus
Chief Financial Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2023-06-16−9,500→ 183,119 totalExercise: $3.63Exp: 2032-06-28→ Common Stock (9,500 underlying) - Exercise/Conversion
Common Stock
2023-06-16$3.63/sh+9,500$34,485→ 29,530 total
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares subject to the option vested on April 20, 2023, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.